Events Accelerating Cell Engineering: From Innovation to Impact

Accelerating Cell Engineering: From Innovation to Impact

Join us for a lunch and learn at Oslo Cancer Cluster

Tuesday, May 20, 2025

9:00 a.m. to 12:00 p.m.

Event details

Location:
Oslo Cancer Cluster Innovation Park
Jonas Einarsson Auditorium
Ullernchausséen 64/66, 0379 Oslo, Norway

Join us for a technical seminar on advanced cell engineering at Oslo Cancer Cluster. This in-person event will feature Anna Pasetto, PhD, director of the Centre for Advanced Cell Therapy (ACT) at Oslo University Hospital, who will share how the ACT Centre is accelerating the development and clinical translation of innovative, cell-based immunotherapies.

You'll also hear from MaxCyte experts Janin Kaper and Jelani Leito, who will present how MaxCyte’s non-viral Flow Electroporation^® technology is enabling high-efficiency, GMP-compliant transfection across a wide range of cell types — including T cells, NK cells and stem cells.

Through real-world case studies, we’ll explore how MaxCyte is supporting advanced therapy development in areas such as CRISPR gene editing, cell therapy manufacturing and translational research.

Enjoy a complimentary lunch, meet with fellow researchers and engage in discussions about the future of non-viral cell engineering in clinical development.

Space is limited — reserve your seat today!

Speakers

Anna Pasetto

Director of the Centre for Advanced Cell Therapy,
Oslo University Hospital

Anna Pasetto is the director of the Center for Advanced Cell Therapy at Oslo University Hospital and an associate professor at the University of Oslo. Previously, she was an assistant professor at Karolinska Institutet, where she managed the pre-GMP facility and remains a research specialist. She earned her master’s in molecular biotechnology from Bologna University in 2007 and a PhD from Karolinska Institutet in 2012. As a postdoctoral fellow at the National Cancer Institute, NIH, Anna studied TCR gene isolation from mutation-reactive TILs in solid cancers. Her goal is to advance novel immunotherapies for cancer treatment.

Janin Kaper

Field Applications Scientist, MaxCyte, Inc.

Janin Kaper is a certified medical laboratory technologist with advanced degrees in cell biology (BSc, University of Lübeck, Germany) and toxicology (MSc, Karolinska Institute; Stockholm, Sweden). With over 10 years of experience in the cell and gene therapy field, Janin has hands-on expertise in process development and optimization for various cell therapies, including T-cells, dendritic cells, tumor-infiltrating lymphocytes, iPSCs and NK cells. Before joining MaxCyte, Janin also supported customers as a field applications scientist, assisting with both upstream and downstream processes of gene editing. Janin’s diverse background, spanning healthcare, research and development, and industry, provides invaluable support to MaxCyte's customers.

Jelani Leito

Business Development Manager, MaxCyte, Inc.

Jelani is the sales manager at MaxCyte covering the Nordic and Benelux regions of Europe. Prior to his time at MaxCyte, Jelani worked as a cell therapy sales specialist at Cytiva covering the same territory. Jelani completed a PhD in biochemistry at the Free University of Amsterdam and has since held several commercial roles in biotechnology.